Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
Follow ELAN by emailGet an email when ELAN pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about ELAN, unsubscribe in one click. Privacy
📣 What ELAN Says Is Next
by 2030 · “"Our faster than expected margin expansion includes good early progress on our Elanco Ascend productivity initiatives, on track to $200 million to $250 million in adjusted EBITDA net savings by 2030.”
Company press release, Aug 5, 2026 · SEC filing
Year-End · “- PRESS RELEASE DATED AUGUST 5, 2026 Document Exhibit 99.1 FOR IMMEDIATE RELEASE Investor Contact: Tiffany Kanaga (765) 740-0314 or tiffany.kanaga@elancoah.com Media Contact: Colleen Parr Dekker (317) 989-7011 or colleen.dekker@elancoah.com Elanco Animal Health Reports Second Quarter 2026 Results Raising Full Year Outlook and Innovation Target, Improving Year-End Net Leverage Ratio Target”
Company press release, Aug 5, 2026 · SEC filing
Year-End · “PRESS RELEASE DATED MAY 6, 2026 Document Exhibit 99.1 FOR IMMEDIATE RELEASE Investor Contact: Tiffany Kanaga (765) 740-0314 or tiffany.kanaga@elancoah.com Media Contact: Colleen Parr Dekker (317) 989-7011 or colleen.dekker@elancoah.com Elanco Animal Health Reports First Quarter 2026 Results Raising Full Year Outlook and Innovation Target, Improving Year-End Net Leverage Ratio Target”
Company press release, May 6, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Get the full ELAN picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ELAN and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.